Health
Ohio mother hopes for a cure to save her son, 8, from rare, fatal disease: ‘Gut-wrenching’
For the three out of every 100,000 children who are born with Batten disease, the diagnosis is one of the most devastating that a family can receive.
Emily Blackburn, 32, found out in March 2023 that her 7-year-old son, Grayson Naff, has the rare, genetic, fatal disorder.
Now, the Ohio family is faced with the harsh reality that Naff will ultimately lose his sight, then his cognitive abilities and motor skills.
The life expectancy for children with Batten disease is usually five or six years after symptoms begin.
HEART DISEASE RISK INCREASES FOR YOUNG ADULTS WHO HAVE LOST A SIBLING, STUDY FINDS
Shortly before her son started first grade, Blackburn took him to the eye doctor for what she thought was a routine visual exam.
She’d noticed it was more difficult for him to see the TV screen, so she assumed he needed glasses.
Grayson Naff, 8, pictured at right and with his family, was diagnosed with Batten disease in spring 2023. “I really don’t have words for it,” said mom Emily Blackburn to Fox News Digital. (Emily Blackburn)
During the exam, the doctor noticed something concerning in Naff’s retina and sent the family to a retina specialist in Cincinnati.
“At first, they thought that it was a disease called Stargardt, which is where you lose your central vision and become legally blind,” Blackburn told Fox News Digital in an interview.
That was heartbreaking in itself, she said — “enough to send you into a spiral” — but things got even worse when the doctors decided to do some genetic testing to confirm the diagnosis.
Grayson Naff was 7 when he was diagnosed with Batten disease. He still attends his same public school, where he is in second grade. (Emily Blackburn)
It turned out the first diagnosis was incorrect. And with tears in their eyes, the geneticists informed Blackburn during a Zoom call that her son actually had Batten disease.
“We went from thinking our son would become legally blind to finding out that he has this fatal disease with no cure,” Blackburn said. “I really don’t have words for it. It’s unbelievable. It’s soul-crushing.”
What is Batten disease?
A fatal genetic disorder, Batten disease interferes with the body’s ability to eliminate cellular waste, per Cleveland Clinic’s website.
As the excess lipids and proteins build up, they cause vision loss, seizures, cognitive decline, impaired mobility and death.
There is currently no cure for the disorder.
“It’s unbelievable. It’s soul-crushing.”
Batten disease is usually diagnosed through genetic testing, when an abnormal change is found in one of the several genes associated with the disease, noted Christelle Moufawad El Achkar, M.D., a neurologist in the Division of Epilepsy and Clinical Neurophysiology at Boston Children’s Hospital.
There are 13 different types of Batten disease, each involving a different gene. Naff was diagnosed with CLN3.
Grayson Naff is pictured with his little brother. “Grayson is such a great big brother to Beckett,” Blackburn said. “They’re best friends.” (Emily Blackburn)
“Within each gene, there can be different clinical subtypes with different ages of onset and severity, starting from infancy until adulthood,” Moufawad El Achkar told Fox News Digital.
“This can make diagnosis harder, especially in the early stages of the disease.”
Early diagnosis is very important, the doctor emphasized, especially because some types of disease can be slowed with therapies.
PENNSYLVANIA MOTHER AND SON BOTH BORN WITH RARE GENETIC DISEASE: ‘CLOSER BECAUSE OF THIS’
Early symptoms of Batten include loss of balance, falls and slurring of speech.
Epilepsy or seizures can be an early sign in some subtypes, but might only happen later in some patients, said Moufawad El Achkar.
Gradual loss of vision is seen in almost all patients at some point in the disease.
“We try to keep him as educated as we can on his vision while still allowing him to be the same little boy he is now,” Naff’s mother told Fox News Digital. (Emily Blackburn)
“It is crucial to suspect and test for Batten disease in any child who has loss of skills, especially if accompanied by seizures, at any age,” the doctor said.
As her son’s vision had already declined considerably at the time of his diagnosis, it is now 20/200, which qualifies as legally blind, Blackburn shared.
Only his vision has been impacted so far, but doctors have warned Blackburn of what’s to come over the next couple of years — including dementia, decline in motor skills and seizures.
Grayson Naff will have an EEG (electroencephalography) each year to monitor his brain waves for seizure activity. (Emily Blackburn)
As of now, he only knows about his vision struggles — Blackburn has not told him about the Batten disease diagnosis.
“We try to keep him as educated as we can on his vision while still allowing him to be the same little boy he is now,” Blackburn told Fox News Digital.
“We feel like the weight of all the other symptoms is just too hard, too much for him to carry.”
MUSCULAR DYSTROPHY BREAKTHROUGH: FDA APPROVES FIRST-EVER GENE THERAPY FOR RARE CHILDREN’S DISEASE
Naff still attends the same public school, where he works with a teacher for the visually impaired.
“We have amazing teachers and amazing friends in our community,” Blackburn said.
Multidisciplinary care
Patients affected by Batten disease need a multidisciplinary team to help manage their symptoms and design a plan to provide the best quality of life possible, Moufawad El Achkar noted.
Naff’s primary care team is at Nationwide Children’s Hospital in Columbus, Ohio.
Twice a year, the family drives to the University of Iowa Hospitals & Clinics to see an eye doctor, who prescribes an experimental medicine to help preserve Naff’s vision for as long as possible.
Twice a year, the family drives to the University of Iowa Hospitals & Clinics to see an eye doctor, who prescribes an experimental medicine to help preserve Naff’s vision for as long as possible. (Emily Blackburn)
They also travel to Texas Children’s Hospital in Houston to see a neurologist.
Naff will have an EEG (electroencephalography) each year to monitor his brain waves for seizure activity.
He is currently taking a medication called Miglustat, which could help to ease or slow down symptoms. Although the drug is FDA-approved for another condition called Gaucher disease, it is not yet approved for Batten.
“Since it’s not FDA approved, it has a hefty copay cost — if insurance doesn’t cover it, it’s about $100 a pill, or $9,000 a month,” Blackburn said.
PENNSYLVANIA PARENTS HONOR THEIR DAUGHTER WHO DIED OF A RARE GENETIC DISEASE: ‘SWEETEST GIRL IN THE WORLD’
Through an initiative called Guiding Grayson, the family has held events to help raise money for Naff’s costly care.
“Having the support from our community and our friends has been one of the best things to come out of this,” said Blackburn.
All the funds raised for Naff have gone toward the cost of the Miglustat.
“We feel like the weight of all the other symptoms is just too hard, too much for him to carry.”
Blackburn has quit her job as a project manager so she can dedicate her time to taking care of Naff and her younger son.
“There are a lot of unknowns and a lot of scary things, but we hope that the medication can hold off Grayson’s symptoms for as long as possible until there’s a cure,” she added.
Clinging to hope
Because each gene involved in the various types of Batten disease has a different mechanism, finding treatment for each one has been a very difficult process, noted Moufawad El Achkar.
“There have been some oral medications that over time might have shown some delay in the progression of the disease, but none have been shown to affect the course of the disease,” she said.
Through an initiative called Guiding Grayson, the family has held fundraising events to help collect money for Naff’s costly care. (Emily Blackburn)
A drug called Cerliponase Alpha has been shown to significantly slow down symptoms of Batten disease type 2, noted Moufawad El Achkar.
Gene therapies have also been developed for some types and are in early clinical trial stages, but have not yet been administered in the U.S.
Emily Blackburn is pictured with her family. Grayson Naff, center, is now legally blind due to his Batten disease. (Emily Blackburn)
“Research is ongoing to look for therapies for virtually all of the subtypes, but most are at the pre-clinical stage at this time,” said Moufawad El Achkar.
“A lot of strides have been made, but we need a lot more treatment options to be developed, tailored to each subtype, and we need them as soon as possible.”
“Collaboration between scientists, medical teams and family associations all over the world is absolutely necessary to make any meaningful progress in treating these extremely rare disorders,” the doctor added.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Blackburn said she is holding out hope for a cure in her son’s lifetime.
“Scientists are working tirelessly to try to find a cure for this disease,” she said. “It just takes a while for gene therapy to be approved, so that’s what is scary.”
“One of our main goals is to raise awareness for research and funds for a cure — and just to let Grayson know how much we love him.”
“Some days, I’m really hopeful and I feel like Grayson can beat this, and then some days it’s just debilitating and gut-wrenching — it feels like we’re in a nightmare,” Blackburn went on.
“One of our main goals is to raise awareness for research and to raise funds for a cure — and just to let Grayson know how much we love him.”
For more Health articles, visit www.foxnews.com/health.
Health
Could ‘humanmaxxing’ actually help you live longer? Here’s what experts say
Medical expert analyzes trending IV therapy, concerns about peptides
Dr. Mike Varshavski joins ‘Fox & Friends’ for Wellness Week, examining trending self-care treatments. He evaluates IV vitamin therapy, highlighting its hospital-critical role versus unproven benefits for general wellness, citing potential risks like vitamin imbalance. Dr. Mike also differentiates creatine, a research-backed supplement, from unregulated peptides marketed with unverified anti-aging and muscle growth promises, urging caution for patients.
NEWYou can now listen to Fox News articles!
We are officially living in the “maxxing” era.
From “looksmaxxing” to improve appearance to “sleepmaxxing” for better rest, these viral terms all point to the same goal: squeezing every ounce of potential out of a specific trait or habit.
With a growing focus on optimizing wellness and maximizing longevity, the trend has evolved into what’s known as “humanmaxxing,” sparking a bigger question: How far can people go to optimize the human body?
ANTI-AGING BENEFITS LINKED TO ONE SURPRISING HEALTH HABIT
While there is no single definition of humanmaxxing, the trend generally refers to efforts to optimize health, performance and longevity through a combination of lifestyle habits, health tracking, supplements and, in some cases, more experimental interventions.
While there is no single definition of humanmaxxing, the trend generally refers to efforts to optimize health, performance and longevity through a combination of lifestyle habits, health tracking, supplements and, in some cases, more experimental interventions. (iStock)
For some, the movement begins with biohacking. According to Dave Asprey, a Texas-based wellness expert who refers to himself as the “father of biohacking,” optimizing your body starts with changing your environment.
Asprey has defined biohacking as “the art and science of changing the environment around you or inside you so that you have full control of your own biology.”
COULD HUMANS LIVE TO BE 150 YEARS OLD? GENETICIST SHARES WHY IT MAY BE POSSIBLE
His public advice focuses on boosting cellular energy through everyday choices like intermittent fasting, high-fat diets, red-light therapy and supplement routines.
“My goal right now is 180 years, because I’m doing something about it now instead of waiting,” he once said.
Clinical experts warn that extreme self-experimentation skips the rigorous safety checks that typical medical science requires. (iStock)
Others have embraced a more data-driven approach. Tech entrepreneur Bryan Johnson, creator of the multimillion-dollar longevity project Blueprint in Los Angeles, argues that optimizing the body means removing human error from health decisions and instead relying on medical data.
“Methodically, we sought to build an algorithm with science and data that could better care for me than I can myself,” Johnson wrote on his website. “My mind did not have the authority to override the algorithm.”
THINKING ABOUT PEPTIDES? DOCTORS REVEAL KEY DOS AND DON’TS AS ‘WILD WEST’ MARKET GROWS
Johnson’s routine involves tracking hundreds of health metrics, eating a precisely measured diet, taking dozens of supplements, and undergoing advanced medical treatments in an effort to reduce his biological age.
CLICK HERE FOR MORE HEALTH STORIES
At the far end of the spectrum are those investing in technologies aimed at pushing the limits of human performance.
London-based tech investor Christian Angermayer recently described humanmaxxing as a strategy toward human maximization.
Tech entrepreneur Bryan Johnson, creator of the multimillion-dollar longevity project Blueprint, argues that optimizing the body means removing human error from health decisions and instead relying on medical data. (iStock)
“I don’t think we should become something different, because I think humans are awesome, but I think we can maximize the potential [that] is already in us,” he said in an interview with The New York Times.
Angermayer’s investment firm, Apeiron Investment Group, focuses on technologies intended to help people “live longer, healthier and more fulfilling lives.” He also founded atai Life Sciences, a biotechnology company that develops psychedelic treatments for mental health conditions that are currently being evaluated in clinical trials.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
As interest in humanmaxxing grows, mainstream health experts urge consumers to separate evidence-based wellness practices from experimental interventions.
Public guidance from the National Institute on Aging notes that while some anti-aging therapies have shown promise in laboratory research, there is not yet sufficient evidence that they can safely extend human life.
As interest in humanmaxxing grows, mainstream health experts urge consumers to separate evidence-based wellness practices from experimental interventions. (iStock)
Clinical experts also caution that extreme self-experimentation can bypass the rigorous safety standards applied to conventional medical treatments.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
According to the Endocrine Society, taking substances such as testosterone or growth hormone without a medical need can lead to serious health risks, including cardiovascular complications and long-term disruption of the body’s chemical balance.
While many humanmaxxing habits overlap with standard healthy lifestyle practices, experts say consumers should be cautious of expensive or experimental interventions that promise dramatic anti-aging or longevity benefits without strong scientific evidence.
Health
New blood test detects 90% of aggressive prostate cancer cases, beating current screenings
NEWYou can now listen to Fox News articles!
A new test could make it easier to detect high-risk prostate cancer cases earlier.
The blood test, called Stockholm3, is showing promise in clinical trials, beating out the traditional, standard prostate-specific antigen (PSA) test.
In a new study published in the Annals of Internal Medicine, researchers from the Karolinska Institutet in Sweden studied the test’s efficacy in more than 12,000 men — mostly Swedish or European — aged 50 to 74.
NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS
All participants were tested with PSA and Stockholm3 and were followed for two years. During the follow-up period, 443 men were diagnosed with aggressive prostate cancer.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests. (iStock)
Stockholm3 missed “significantly fewer” serious cancer cases than PSA. The number of men incorrectly classified as high-risk was similar across both tests, according to a press release.
Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, wrote in a statement that one of the major challenges in prostate cancer is being able to identify the cases that are “truly dangerous.”
‘DILBERT’ CREATOR’S DESPERATE PLEA SHINES SPOTLIGHT ON ALTERNATIVE PROSTATE CANCER DRUG
“Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA without increasing the number of unnecessary follow-ups,” she said.
“These results point toward a potential change in how prostate cancer screening can be conducted,” the researcher added. “A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures.”
“A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures,” a researcher commented. (iStock)
Study co-author Hari Vigneswaran, chief medical officer of Stockholm3-maker A3P Biomedical, commented on these “promising” findings in an interview with Fox News Digital.
PROSTATE CANCER SCREENING AFTER 70: EXPERTS QUESTION GUIDANCE AFTER BIDEN’S DIAGNOSIS
He confirmed that the PSA has been the standard for prostate cancer screening since the 1990s despite its “well-documented limitations.”
CLICK HERE FOR MORE HEALTH STORIES
“It leads to invasive and costly follow-up testing, contributes to over-diagnosis of non-aggressive cancers and, most importantly, it misses a substantial share of aggressive disease,” Vigneswaran said.
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival is close to 100%. (iStock)
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%, which highlights the importance of early detection, according to the doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Data from the National Cancer Institute’s SEER database show that metastatic prostate cancer has risen over the past decade, suggesting that “we have not improved early detection of the aggressive, curable disease that screening is meant to catch,” Vigneswaran said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The goal of screening is to find the cancers that need treatment while they are still curable, without raising the number of men who screen positive but don’t have aggressive disease,” he said.
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher. (Getty Images)
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher.
The findings did have some limitations. Stockholm3 is an investigational device and is not available for sale in the U.S., Vigneswaran noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The test estimates a man’s risk of aggressive prostate cancer, but a biopsy remains the gold standard for confirming the disease.
The company plans to seek FDA approval to use the test for routine screening and will “generate the evidence needed to support that pathway, including U.S. data,” Vigneswaran said.
Health
This Protein Smoothie Trick Helps Women Over 40 Lose Twice as Much Fat
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
-
Lifestyle23 minutes ago‘House of the Dragon,’ Season 3, Episode 2: Honey, I’m home!
-
Technology33 minutes agoChina’s Z.ai claims it can match Mythos on cybersecurity
-
World38 minutes agoShipping giant warns Strait of Hormuz chaos is ‘new normal’ as Tehran shifts 4M barrels
-
Politics45 minutes agoJacob Frey praises Somali community as Minnesota faces renewed scrutiny over fraud investigations
-
Sports53 minutes agoJ.T. Poston posts a 12 on a single hole at Travelers Championship in stunning meltdown
-
Technology1 hour agoMidjourney’s wild body scanner scans you in water
-
Business1 hour agoWhy tech stocks are getting hammered
-
Entertainment1 hour ago
Sigh. Again? ‘Love Island USA’ confirms another contestant fired over apparent use of racial slur